Both false positives and false negatives do occur. In a clinical study of Cologuard, 13% of people without cancer or precancer tested positive (87% specificity). Any positive should be followed by a diagnostic colonoscopy. Following a negative result, patients should continue participating in a screening program at an interval and with a method appropriate for the individual patient. Cologuard performance when used for repeat testing has not been evaluated or established.
*Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med. 2014;370(4):1287-97.
Cologuard uses a special kind of technology that’s quite innovative. It’s called sDNA (stool DNA) technology and it detects cancer and highest-risk precancers. It makes Cologuard the most accurate, noninvasive colon cancer screening test that you can rely on. Learn more »